Provided by Tiger Trade Technology Pte. Ltd.

Anaptysbio Inc

44.51
+0.16000.36%
Pre-market: 44.510.00000.00%06:03 EST
Volume:300.44K
Turnover:13.44M
Market Cap:1.23B
PE:-15.48
High:46.56
Open:45.35
Low:44.21
Close:44.35
52wk High:46.56
52wk Low:12.21
Shares:27.69M
Float Shares:14.25M
Volume Ratio:0.55
T/O Rate:2.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8757
EPS(LYR):-5.1170
ROE:-308.02%
ROA:-4.23%
PB:-41.90
PE(LYR):-8.70

Loading ...

A Look at AnaptysBio's Valuation as Litigation With GSK Over Jemperli Royalties Draws Investor Focus

Simply Wall St.
·
Nov 28

BRIEF-AnaptysBio's Complaint Against Tesaro For Breaching Agreement Was Publicly Filed On Nov 26 - SEC Filing

Reuters
·
Nov 27

AnaptysBio Inc - on Nov 26, Co's Complaint Against Tesaro for Breaching Agreement Was Publicly Filed - SEC Filing

THOMSON REUTERS
·
Nov 27

Wedbush Sticks to Its Buy Rating for AnaptysBio (ANAB)

TIPRANKS
·
Nov 26

AnaptysBio Presents Opportunity Despite 'Near-Term Turbulence' Amid Legal Dispute with GSK, Wedbush Says

MT Newswires Live
·
Nov 24

AnaptysBio Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 24

BUZZ-U.S. STOCKS ON THE MOVE-IES Holding, Eli Lilly, Alphabet

Reuters
·
Nov 22

Sector Update: Health Care Stocks Rise Pre-Bell Friday

MT Newswires Live
·
Nov 21

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday on Reignited Rate Cut Hopes

MT Newswires Live
·
Nov 21

BUZZ-AnaptysBio tumbles after latest legal battle over cancer drug

Reuters
·
Nov 21

Top Premarket Decliners

MT Newswires Live
·
Nov 21

AnaptysBio initiates litigation against GSK subsidiary Tesaro

TIPRANKS
·
Nov 21

AnaptysBio announces $100M share repurchase program

TIPRANKS
·
Nov 21

AnaptysBio Files Complaint Alleging GSK's Tesaro Breached Jemperli Collaboration Deal

MT Newswires Live
·
Nov 21

AnaptysBio Launches $100 Million Share Buyback Program

MT Newswires Live
·
Nov 21

Anaptys Announces $100 Million Stock Repurchase Plan

THOMSON REUTERS
·
Nov 21

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

THOMSON REUTERS
·
Nov 21

GSK Subsidiary TESARO Sues AnaptysBio Over Jemperli License Dispute

Reuters
·
Nov 21

GSK: Tesaro, a GSK Subsidiary, Initiates Litigation Against AnaptysBio, Inc

THOMSON REUTERS
·
Nov 21

GSK: Breach Entitles Tesaro to Terminate Current License Agreement, Obtain a Perpetual and Irrevocable License to Dostarlimab

THOMSON REUTERS
·
Nov 21